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ABSTRACT 
BACKGROUND: This was a national English observational cohort study using administrative data 
to estimate the effectiveness of community pharmacological and psychosocial treatment for alcohol 
use disorder (AUD).  
 
METHODS: All adults commencing AUD treatment in the community reported to the National Drug 
Treatment Monitoring System (April 1 2014 to March 31 2015; N=52,499). Past 28 day admission 
drinking pattern included drinks per drinking day (DDD): 0 (‘Abstinent’), 1-15 (‘Low-High’), 16-30 
(‘High-Extreme’) and over 30 DDD (‘Extreme’). The primary outcome was successful completion of 
treatment within 12 months of commencement with no re-presentation (SCNR) in the subsequent six 
months, analysed by multi-level, mixed effects, multivariable logistic regression.  
 
RESULTS: The majority reported DDD in the ‘Low-High’ (n=17,698, 34%) and ‘High-Extreme’ 
(n=21,383, 41%) range. Smaller proportions were categorised ‘Extreme’ (n=7,759, 15%) and 
‘Abstinent’ (n=5,661, 11%). Three-fifths (58%) achieved SCNR. Predictors of SCNR were older age, 
black/minority ethnic group, employment, criminal justice system referral, and longer treatment 
exposure. Predictors of negative outcome were AUD treatment history, lower socio-economic status, 
housing problems, and ‘Extreme’ drinking at admission. In addition to psychosocial interventions, 
pharmacological interventions and recovery support increased the likelihood of SCNR. 
Pharmacological treatment was only beneficial for the ‘Low-High’ groups with recovery support.  
 
CONCLUSIONS: Over half of all patients admitted for community AUD treatment in England are 
reported to successfully complete treatment within 12 months and are not re-admitted for further 
treatment in the following 6 months. Study findings underscore efforts to tailor AUD treatment to the 
severity of alcohol consumption and using recovery support.  
 
KEYWORDS: alcohol; treatment; alcohol use disorder; psychosocial; pharmacological; recovery
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1. Introduction 
 
Reducing alcohol-related harms is a global public health priority (World Health Organisation, 2014). 
Alcohol consumption is linked to over 200 disease and injury conditions and implicated as a cause in 
3.8% of all global deaths (Rehm et al., 2009). Each year, 3.6% of the global population (15-64 years) 
meet diagnostic criteria for alcohol use disorder (AUD; American Psychiatric Association, 2013) with 
higher rates estimated for Europe (5.5%) (Rehm et al., 2009). AUD is characterised as a chronic 
relapsing disorder, often associated with several presentations to treatment (Dennis et al., 2005).  
 
Facilitating access to effective treatment is a key priority for most countries with developed healthcare 
systems. In the United Kingdom (UK), the National Institute for Health and Care Excellence (NICE; 
2011) guidelines have identified a range of formal, randomised controlled trial (RCT) supported 
psychosocial and pharmacological interventions for the management of AUD (see Donoghue et al., 
2015; Jonas et al., 2014; Martin and Rehm, 2012).  
 
In England, public treatment systems for alcohol-related problems are commissioned by local 
government authorities in accordance with NICE guidance. Most AUD treatment is offered by 
National Health Service (NHS) and third sector services in primary and secondary care 
community/outpatient settings, the latter delivered by multi-disciplinary teams which typically include 
psychiatrists/physicians, psychiatric/general nurses, psychologists, social workers, and counsellors. 
There is also small number of inpatient and residential programs provided by the NHS and third 
sector.  
 
Psychosocial interventions, delivered individually or in a group format, variously apply motivational, 
cognitive, behavioural, psychodynamic, family and social network methods. They provide access to 
general counselling, community support networks and 12-step groups to support abstinence or 
prevention of heavy drinking. Therapeutic targets vary and include resolving ambivalence about 
change and improving recognition of, and control over, alcohol conditioned cues, urges and emotions. 
These interventions vary in duration, from approximately 3 to 20 sessions according to the severity 
and complexity of the person’s AUD and the methods involved.  
 
Pharmacological interventions are used to help patients withdraw from alcohol and for relapse 
prevention. Withdrawal regimens, usually incorporating benzodiazepine medications, are typically for 
7-10 days. Specific medications targeting the brain’s reward and stress systems, including 
acamprosate, naltrexone, and nalmefene (Mason et al., 1999), help those who have stopped using 
alcohol maintain abstinence or prevent heavy drinking. These medications are usually provided for 6 
months or longer with psychosocial support. In the context of continuing care, formal psychosocial 
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and pharmacological interventions may be delivered concurrently or sequentially within specific 
episodes.  
 
In developed healthcare systems, AUD treatment plans incorporate information on the clinician 
history, patient preference, current clinical severity, case complexity, and service availability. In the 
UK, NICE (2011) guidelines are based on a delineation of treatment interventions according to level 
of consumption on a typical drinking day at assessment, as follows: people consuming ≤15 drinks per 
drinking day (DDD; one unit = 10mL, containing 8mg pure alcohol) are recommended for 
psychosocial interventions; those consuming 16-30 DDD should be assessed are recommended for 
pharmacological treatment to for assisted withdrawal, coupled with appropriate psychosocial 
interventions; and for those consuming 30 DDD, there should be assessment for a 24-hour medically 
supervised residential program.    
 
Since 2005/06, the English National Drug Treatment Monitoring System (NDTMS; Public Health 
England, 2015b) has monitored access to treatment for drug use disorders and measuring associated 
outcomes. In 2008/09, NDTMS was enhanced to monitor outcomes from all public treatment services 
for AUD. Today, all operational public alcohol and drug treatment services who deliver treatment 
interventions report to the system and ~98% of patients consent to the use of their administrative and 
clinical data for local treatment system needs assessment and national research (Marsden et al., 2009; 
Marsden et al., 2012; White et al., 2015; Willey et al., 2016).  
A crucial question for alcohol policy and public accountability is whether public treatment services 
for AUD are effective. There has been remarkably little research on this question in the UK or 
overseas. For several reasons, routine effectiveness in the clinic may differ to results from RCTs and 
systematic reviews. Clinical trials conducted in this area typically involve specified treatment 
protocols, delivered within a single setting to patients categorised by a set threshold of severity 
(usually with criteria imposed to minimise risk of poor response; Witkiewitz et al., 2015). Such 
restrictions may not apply to the general treatment population, who present with a wide range of 
clinical severity and health and social complexities. Understanding those characteristics which predict 
treatment outcomes for this diverse population is critical for targeting services, facilitating prognosis, 
and improving treatment outcomes (Adamson et al., 2009).  
 
There has been no national study to date on the clinical effectiveness of community AUD treatment 
services in the UK, with previous reports focusing on treatment provision (Brennan et al., 2005) and 
recidivism (Willey et al., 2016). For England, we report on the clinical outcomes for AUD associated 
with pharmacological and psychosocial interventions.  
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2. Methods 
 
2.1  Design 
This was an observational, follow-up study of people accessing publicly-funded, community-based, 
treatment for AUD in England. A report on the effectiveness of residential treatments is reported 
elsewhere (Eastwood et al., under review). Data were collected from all community based treatment 
agencies providing structured psychosocial and pharmacological interventions for AUD and reporting 
to NDTMS (Public Health England, 2015b). The study included all 152 upper-tier local authorities 
within England, and all specialist AUD services within the National Health Service or third-sector 
reporting to the database. The study is reported according to the STROBE (and RECORD) guideline 
for cohort research (Benchimol et al., 2015).  
 
2.2 Patient and treatment information 
NDTMS records were accessed on patient-demographic, behavioural, clinical and treatment outcome 
variables for each episode of treatment, including the dates of starting and finishing AUD 
interventions (Public Health England, 2015a, b). Reflecting national reporting standards (Public 
Health England, 2015b), and utilising a pre-existing variable in the database, individual treatment 
episodes were concatenated into ‘treatment journeys’, whereby multiple episodes (community-based 
or residential program) are subsumed under a single journey.  
 
AUD intervention episodes were allocated to the same treatment journey if fewer than 21 days 
elapsed between the date of ending one intervention and the date of starting a subsequent one. In this 
way, a treatment journey for a patient could comprise a single intervention episode; concurrent 
episodes provided by more than one agency; or a continuing care package of consecutive episodes 
provided by one or more service providers.  
 
2.3  Study cohort 
The study population was adults (aged ≥18 years) who commenced community treatment for primary 
AUD between 1 April 2014 and 31 March 2015 (N=54,354). Patients were not included in the study 
cohort if they: (1) reported problematic use of other substances at assessment; (2) had missing 
information on DDD at both triage and treatment admission; or (3) had missing information on 
clinical status at discharge were not considered for inclusion. Following removal of 1,425 cases who 
were assessed but then received no treatment, the analysis cohort comprised 52,499 individuals.  
 
Analyses were based on the patients’ first treatment journey during the period (hereafter ‘index 
journey’). The observation period commenced from the date of starting community-based structured 
treatment and ended either six months after the date of discharge from the index journey, if discharge 
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occurred within 12 months of starting treatment; or 12 months after starting treatment if the patient 
was not yet discharged (the latter group was excluded from analysis of the primary outcome). 
 
2.4 Outcome measure 
A commonly used measure of treatment outcome is the proportion of patients treated who complete 
treatment successfully (i.e., discharge from treatment based on reduced alcohol use or abstinence, 
depending on treatment goals; Alterman et al., 2001). Whilst this outcome is associated with reduced 
alcohol use and improved social outcomes (e.g., employment, offending) (Finigan, 1996), it does not 
identify the extent to which the treatment effect is enduring beyond the clinical setting, critical given 
high rates of relapse.  
 
The primary outcome measure for the current study was defined as successful completion of treatment 
within 12 months of admission for community-based treatment, with no re-presentation for AUD in 
the subsequent six months (i.e. ‘successful completion and no representation' [SCNR]). Successful 
treatment was defined as the patient being discharged having completed their care plan, abstinent (or 
no heavy drinking), and with no re-presentation to any service for further AUD treatment within six 
months (Eastwood et al., 2017; Public Health England, 2016). In this categorisation, no re-
presentation is proxy indicator of remission.  
 
All treatment journeys were categorised according to clinical assessment of patients’ discharge status, 
as follows: (1) successfully completed treatment within 12 months (i.e., client no longer requires 
structured drug treatment interventions and is judged by the clinician not to be using heroin (or any 
other opioids) or crack cocaine or any other illicit drug); (2) retained in the same treatment journey at 
12 months from entry; (3) withdrawn from index treatment journey within 12 months of entry due to 
unsuccessful transfer between service providers; or (4) treatment terminated due to incarceration or 
patient dropped out of or died during treatment (Public Health England, 2015b). 
 
2.5 Covariates 
Following our general evaluation approach (Willey et al., 2016), the analysis included patient socio-
demographics; indicators of clinical severity/case complexity; and summary measures of treatment 
journey exposure. Patient-level measures were recorded at triage assessment at the first admission to 
the index journey. The following covariates were included. 
 
2.5.1 Socio-demographics 
Analyses were adjusted for: age (years), gender, ethnic origin, housing problems (homeless, in short-
term hostel provision, or at risk of eviction in the past 28 days); and employment (whether in paid 
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work in past 28 days). Analyses were also adjusted for an indicator of social deprivation, imputed by 
assigning patients to their electoral ward of residence, based on the partial postal code recorded by 
NDTMS, categorised according to the Department for Communities and Local Government ward-
level Indices of Multiple Deprivation (IMD; Department for Communities and Local Government, 
2015). If the partial postcode could be located in more than one electoral ward the median IMD score 
for these was assigned. If partial postcode was missing the IMD score for the first treatment service 
address within the index treatment journey was assigned. Following UK local government reporting 
convention (Public Health England, 2015a), IMD scores were grouped by quintile.  
 
2.5.2 Clinical characteristics 
Analyses were adjusted based on patients’ self-report of the number of days on which they consumed 
alcohol; and the number of standard DDD in the previous 28 days (Tuithof et al., 2014). These were 
recorded via the Treatment Outcomes Profile (TOP) (Marsden et al., 2008). TOP is the national 
clinical outcome measure in NDTMS, administered as a face-to-face structured clinical interview, 
with timeline follow-back technique to maximise recall accuracy (Sobell et al., 1988). Reflecting 
NICE (2011) guidelines for treatment provision based on alcohol use on treatment admission, DDD 
were categorised as: abstinent (i.e. zero drinks in the previous 28 days); low to high (1 to 15 DDD); 
high to severe (16 to 30 DDD); and extreme ( 31 DDD). We also adjusted for source of treatment 
referral (health service; self/friend/family; criminal justice system), and whether the patient had 
previously received AUD treatment as recorded in NDTMS (i.e., from 2006 onwards). 
 
2.5.4 Treatment exposure  
Analyses were adjusted based on the combination of treatment type exposure within the index 
treatment journey, as follows: (1) psychosocial treatment only; (2) psychosocial and pharmacological 
treatment; (3) psychosocial treatment and recovery support; and (4) psychosocial and pharmacological 
treatment and recovery support. Recovery support was via direct treatment service provision or 
referral, including facilitated access to mutual aid; peer support involvement, family, parenting, 
support groups; housing, employment, education and training support; and complementary therapies. 
The number of days in receipt of psychosocial and pharmacological interventions was right censored 
at 365 days, computed using the triage and discharge date for the specific intervention.  
 
2.6 Statistical Analysis  
In this national treatment population study, with a hierarchical design (i.e. participants grouped in 
treatment services) our statistical power concerns reflected control of clustering effects and 
minimising bias of coefficient estimates in the models. We note that multi-level simulation studies 
have concluded that power is increased by adding groups rather than the number of cases per group. 
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In the event, our sample (636 AUD services) well exceeded the minimum recommended for multi-
level designs (e.g. 50 groups for random effects models; Maas and Hox, 2005).  
 
All analyses were conducted in Stata v13.1 (Stata version 13.1; Stata Corporation, College Station, 
TX, USA). All estimates were computed with associated 95% confidence intervals (95% CI). For the 
DDD measure, a multi-level, multinomial logistic regression approach (command: mlogit) with robust 
standard errors was used to adjust for clustering of participants within treatment services. Analysis of 
the SCNR outcome excluded people who did not leave treatment within 12 months after treatment 
initiation.  
 
Where data for employment, housing status, days of alcohol use and DDD were missing from 
standard assessment procedures, these were replaced with data from the first TOP interview where 
available. Missing values were observed for housing (n=483), employment (n=1,154), ethnic origin 
(n=1,898) and referral source (n=174). With no contrary evidence that data loss was missing-at-
random (Little and Little, 2002), multiple imputation via chained equations was used (Stata command: 
mi: impute chained). An all-case multivariate logistic model was run to check on potential bias and 
loss of precision (Sterne et al., 2009). To achieve a relative efficiency above 98% (Rubin, 1987) and 
to ensure that reduction in power was less than 1% (Graham et al., 2007), 20 datasets of probabilistic 
values were created, each analysed separately, and then combined using Rubin’s rules. 
  
Multi-level, mixed effects, multivariable logistic models were used to assess the SCNR outcome 
(command meqrlogit with 7 integration points) with patient-level covariates included as fixed effects. 
It was anticipated that the likelihood of SCNR, and predictors of SCNR, would vary by baseline 
severity given that baseline alcohol consumption is prognostic factor for treatment outcomes 
(Adamson et al., 2009). Consequently, sub-analyses were conducted where predictors of SCNR were 
studied by drinking severity at admission (indexed by DDD, see section 2.5.2). The ‘High-Extreme 
group’ served as referent for total sample analyses as the group whose alcohol use most closely 
aligned with NICE guidelines (National Institute for Health and Care Excellence, 2011) indicating 
delivery of community-based treatment. Simulation studies suggest a minimum of 10 or more events 
per covariate in logistic regression analyses; this criterion was satisfied in the current analyses 
(Peduzzi et al., 1996). Models based on imputation are reported in-text; complete-case analyses are 
available in supplementary materials.  
 
3. Results 
3.1 Socio-Demographic/Clinical Characteristics  
The majority of patients were male (62%) and the median age was 45 years (IQR 36-53) (Table 1). 
Two-fifths (38%) had received structured AUD treatment prior to their index journey.  
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For the majority, DDD status was categorised as ‘Low-High’ (34%) or ‘High-Extreme’ (41%). Of the 
remainder, 15% were designated ‘Extreme’ and 11% as ‘Abstinent’. The ‘Extreme group’ were more 
likely to be male and younger, to report housing problems, current unemployment, and an AUD 
treatment history, and live in areas with the greatest socio-economic disadvantage, and the ‘Low-High 
group’ the inverse, compared to the ‘High-Extreme group’ (Table 2).  
 
The ‘Abstinent’ group were less likely to be male and in paid employment, and more likely to identify 
as black or minority ethnic group relative to the ‘High-Extreme group’. Notably, all three groups were 
more likely to report criminal justice referral to treatment relative to the ‘High-Extreme group’. 
 
3.2 Treatment Exposure and Status 
The cohort accessed 636 specialist community treatment services (median of 27.5 participants per 
service; IQR 4, 115). In their index journey, 59% received structured psychosocial treatment only; 
26% received psychosocial treatment with recovery support; 10% received psychosocial and 
pharmacological interventions; and 5% received all three (Table 1). The ‘Abstinent group’ and ‘Low-
High group’ were less likely to receive pharmacological treatment, and the ‘Extreme group’ was more 
likely to receive all three interventions, relative to the ‘High-Extreme group’. Median total duration of 
treatment exposure was equivalent to more than four months (18 weeks). Half of the sample (54%) 
successfully completed treatment within 12 months (Table 3). This was inversely related to DDD, 
ranging from 61.1% of the ‘Abstinent group’ to 44.8% of the ‘Extreme group’.  
 
3.3 SCNR outcome  
Half (58%) of those who left treatment within 12 months of commencement (i.e., excluding those still 
in treatment) achieved the SCNR outcome (Table 3). This was more likely among those who were: 
older; identified as black or other ethnic minority; in paid employment; referred to treatment by 
criminal justice services; in receipt of longer treatment exposure; and who received other 
interventions in addition to psychosocial intervention (Table 4). Specifically, the addition of 
pharmacological treatment to psychosocial intervention increased the likelihood of this outcome by 
35%, addition of recovery support by 80%, and addition of both pharmacological intervention and 
recovery support by 147%. This outcome was less likely for those who: lived in areas of greatest 
socio-economic disadvantage; reported housing problems; and reported previous AUD treatment.  
 
Relative to the ‘High-Extreme group’, the ‘Abstinent group’ and ‘Low-High group’ had greater 
adjusted odds (1.80, 95% CI 1.67 to 1.94 and OR 1.31, 95% CI 1.25 to 1.37, respectively), and the 
‘Extreme group’ lower adjusted odds (0.82, 95% CI 0.78 to 0.88) of attaining the SCNR outcome.  
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Testing the model for each DDD group showed similar associations with covariates and the primary 
outcome, with the exception that provision of pharmacological intervention with psychosocial 
intervention was not associated with SCNR for the ‘Abstinent group’ and ‘Low-High group’, although 
the latter group was advantaged when delivered alongside recovery support.  
 
3.3.1 Sensitivity analysis 
The associations identified in the imputed models were generally evident in complete-case analyses 
(Table S1). As a check on potential selection effects risking a positive bias in treatment response, we 
ran a fixed effects logit model and compared with a Heckman selection model. Parameter estimates 
were essentially the same between the two models (all z-values were approximately of the same 
direction, magnitude and statistical significance).  
 
We also calculated the E-value. The E-value is an estimate of the minimum strength of association 
that an unmeasured confounder would need to account for a treatment-outcome association, 
conditional on the included covariates (VanderWeele and Ding, 2017). An observed AOR of 1.35 for 
psychosocial and psychosocial intervention, 1.80 for psychosocial interventions and recovery support, 
and 2.47 for all three interventions could be explained away by an unmeasured confounder that was 
associated with both the treatment and the outcome by a OR of 2.04 (95%CI 1.81-2.30), 3.00 (95%CI 
2.77-3.23), and 4.38 (3.85-4.98), respectively, above and beyond the measured confounders, but 
weaker confounding could not do so. The confidence intervals could be moved to include the null by 
an unmeasured confounder that was associated with both the treatment and the outcome by an OR of 
1.81, 2.77, and 3.85 each, above and beyond the measured confounders, but weaker confounding 
could not do so. 
 
4 Discussion 
 
The current national study provides a unique opportunity to assess community-based intervention 
outcomes for the heterogeneous AUD population. Using the NICE (2011) guidelines, we categorised 
patients according to severity of alcohol use in order to test for differences between these groups. The 
DDD groups differed socio-demographically, particularly in reference to previously identified risk 
factors for poorer treatment outcomes (Adamson et al., 2009). Specifically, the ‘Extreme group’ were 
more likely to be male, younger, live in areas with the greatest socio-economic disadvantage, report 
lower rates of employment, and higher rates of homelessness and past AUD treatment involvement, 
relative to the ‘High-Extreme group’. In contrast, the ‘Low-High group’ were more likely to report 
factors predictive of positive treatment outcomes (e.g., female, older age, lower socio-economic 
disadvantage, higher rates of employment) relative to the ‘High-Extreme group’.  
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Less clear is where the ‘Abstinent group’ fit in terms of previously identified risk factors for poorer 
treatment outcomes.  Similar to the ‘High-Extreme group’ in socio-economic status and AUD 
treatment history, this group were also more likely to be female (correlate of positive treatment 
outcome), younger, and with lower rates of employment (correlates of poorer treatment outcomes) 
(Adamson et al., 2009). Possible explanations for this group include entry into treatment following 
incarceration, noting that this group had the highest rate of referral from criminal justice services, or 
abstinence as a requirement for commencing acamprosate and naltrexone, although only one-tenth of 
this group received pharmacotherapy.  
 
Over half the sample successfully completed treatment; one-quarter ceased treatment, and one-tenth 
were retained in treatment at 12 months. The lack of national treatment monitoring systems in other 
countries (or lack of reporting on these systems) makes cross-national comparison of treatment 
outcomes challenging. Yet,  65% of closed treatment episodes in Australia in 2015-16 where alcohol 
was the principal drug of concern were coded as ‘expected cessation’ (defined as successful 
completion or cessation at expiation or mutual agreement), similar to that recorded in NDTMS 
(Australian Institute of Health and Welfare, 2017). Successful treatment completion is linked with 
greater likelihood of abstinence, lower risk of relapse, and lower engagement in crime. However, 
given the recovery-relapse cycle often associated with AUD, we believe the SCNR outcome is a more 
sensitive indicator of treatment effectiveness in terms of remission, and more meaningful in terms of 
economic and service utilisation burden. The current study showed that patients were more likely to 
achieve the SCNR outcome if they were older, identified as black or other ethnic minority, engaged in 
paid employment, and engaged in treatment for longer. Conversely, patients were less likely to 
achieve the SCNR outcome if they lived in areas with greatest socio-economic disadvantage, reported 
housing problems or had an AUD treatment history. These characteristics have previously been 
identified as predictors of treatment retention (Brorson et al., 2013; Elbreder et al., 2011; Haug and 
Schaub, 2016) with the exception of ethnicity. Ethnicity has been identified as a poor predictor of 
treatment outcome, although the association is not routinely reported (Adamson et al., 2009). Further 
exploration as to why individuals identifying as black or other ethnic minority have similar (or, in this 
instance, better) treatment outcomes despite displaying greater pre-treatment risk factors for poorer 
outcomes is warranted (Tonigan, 2003).  
 
The likelihood of SCNR outcome also increased when pharmacological and recovery support 
interventions were received in addition to psychosocial treatment. These findings reinforce treatment 
guidelines recommending the delivery of psychosocial intervention alongside pharmacological 
treatment (Haber et al., 2009; National Institute for Health and Care Excellence, 2011; Substance 
Abuse and Mental Health Services Administration and National Institute on Alcohol Abuse and 
Alcoholism, 2015). Most importantly, this study highlights the possible benefits of recovery support: 
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the addition of recovery support to psychosocial intervention had a stronger association with SCNR 
than the addition of pharmacological intervention, with the strongest association observed with 
delivery of all three interventions.  
 
It is important to note though that the association between intervention type and the SCNR outcome 
differed according to DDD severity. Positive predictors of the SCNR outcome were: the addition of 
recovery support to psychosocial treatment for the ‘Abstinent group’; the addition of recovery support 
(with or without pharmacological treatment) for the ‘Low-High group’; and the addition of 
pharmacological treatment and/or recovery support for the ‘High-Extreme group’ and ‘Extreme 
group’ (largest magnitude association in the presence of all three interventions). We could not 
determine which pharmacological therapies were being delivered, thus precluding conclusions 
regarding relative efficacy. However, the stronger magnitude association of pharmacotherapy 
provision and SCNR amongst those groups with greater severity of DDD supports use of 
pharmacotherapy for those presenting with moderate to severe dependence (National Institute for 
Health and Care Excellence, 2011). Further, the positive association between recovery support and 
SCNR reinforces the importance of continuing care (e.g., recovery check-ups, facilitate access to 
mutual aid) and an emphasis on the broader wellbeing of the individual (e.g., provision of family, 
housing, education and employment support) (Laudet, 2008).  
 
AUD is a chronic condition, often cyclical in nature (Scott et al., 2005a; Scott et al., 2005b). Study of 
long-term recovery has revealed various protective factors, including self-confidence, coping 
strategies, health, financial resources, and quality of family, friend, and work relationships, associated 
with positive AUD outcomes up to 15 years subsequent to treatment (Moos and Moos, 2006). Given 
the remission-relapse cycle and often co-occurring risk factors for poorer quality of life (e.g., 
unemployment, homelessness), these findings highlight the necessity of acknowledging case 
complexity and providing supports to improve broader aspects of functioning. We would advocate for 
further work disentangling the specific forms of recovery support which are efficacious, taking into 
consideration independent and interactive effects of interventions, to inform targeted delivery. In 
addition, it will be important to establish whether these associations hold when predicting re-
presentation to treatment over a longer duration than six months post-discharge. 
 
4.1 Strengths and Limitations 
Representation of individuals seeking AUD treatment across the continuum of DDD severity is a 
strength of this study, indicating fulfilment of the above aim of assessing outcomes across a diverse 
population of alcohol consumers. However, several study limitations should be noted. Firstly, the 
sample was restricted to those who reported only problematic alcohol use. Whilst existing research 
indicates high comorbidity between AUD and other substance disorders (Stinson et al., 2005), annual 
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2014/15 NDTMS data (Public Health England, 2015a) indicates that alcohol only patients formed 
30% of the total treatment population, and patients with comorbid alcohol and non-opiate problematic 
use only 10%. Related to this, severity of use was only indexed by self-reported DDD, meaning that 
assessment was not via established, psychometrically valid scales and may be subject to possible 
recall and social desirability bias.  
 
Secondly, NDTMS does not include other possible correlates of treatment outcomes, such as other 
indicators of social stability and support (e.g., marital status, family structure), self-efficacy, 
personality traits (e.g., impulsivity), treatment goals, and specific co-existing mental health conditions 
(Adamson et al., 2009), and these are recognised a potential unmeasured confounders. Third, we were 
not able to link treatment records to national deaths registry or the national prisons system, meaning 
that we could not censor data for barriers to treatment re-presentation. Given that only 0.2% and 0.9% 
of the sample ceased treatment within 12 months of admission due to incarceration and mortality, 
respectively, we do not anticipate that the rate of SCNR would decrease substantially accounting for 
these factors. Fourth, privately-funded treatment may not be captured in NDTMS, leading to possible 
under-ascertainment of six-month re-presentation following conclusion of the index journey. Finally, 
we should note that the whilst our definition of SCNR matched national reporting standards (Public 
Health England, 2015b), further work using a lengthier period to identify relapse (≥12 months) could 
elucidate longer-term treatment outcomes. 
 
4.2 Conclusion 
The lower likelihood of achieving SCNR among patients with greater DDD at commencement 
highlights the need for additional supports for these patients, particularly given the interplay of 
additional risk factors (e.g., homelessness, unemployment) amongst this group. Provision of 
pharmacological intervention and/or recovery support enhanced the likelihood of achieving SCNR, 
relative to psychosocial intervention alone, although the former was only beneficial for those 
presenting with greater severity alcohol use at commencement. Whilst the relative efficacy of the 
various forms of recovery support and pharmacological intervention requires exploration, these 
findings support the need for a multi-faceted approach to treatment, according to severity of use, with 
a focus on maintaining remission and improving broader aspects of wellbeing.   
 
Appendix A.  Supplementary materials  
Supplementary material related to this article can be found, in the online version, at: XXXXXXX. 
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